A Phase 4 interventional study of EXPAREL and Placebo in Pain, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-02.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Liposomal Bupivacaine in Pain — 5 open to participants now, 5 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain.
Among the 36 studies testing Liposomal Bupivacaine in Pain, this one is the 17th largest by enrollment, is one of 2 that started in 2013, is one of 22 in phase 4, and was the 1st registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →5 of the 36 studies testing Liposomal Bupivacaine in Pain are open now, in 2 countries. Recruiting first, the newest first:
Children's Hospital of Orange County · Sites in United States
Ages 7–17 · Healthy volunteers
Jessyka Lighthall · Sites in United States
Ages 18–99 · Healthy volunteers
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Tongliao City People's Hospital · Sites in China
Ages 18–60
By country, each count listing its studies:
Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 22
First in 2013; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is close to the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 60 across the 36 interventional studies. Of the 24 that completed or were terminated, 21 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
29 studies in Pain by Pacira BioSciences, Inc.: none open now, none under way, none of them phase 3. Of 29 finished, 26 (90%) have results posted.
Among the 29 studies in Pain by Pacira BioSciences, Inc., this one is the 16th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 4, and was the 11th registered.
Pacira BioSciences, Inc.’s Pain studies by the year they started, since 2007.
4 of the studies testing Liposomal Bupivacaine in Pain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07097493Wake Forest University Health SciencesLiposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty | 2027-06 |
| NCT07795203Tongliao City People's HospitalLiposomal Bupivacaine vs Ropivacaine for Post-hemorrhoidectomy Analgesia | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing Liposomal Bupivacaine in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pacira BioSciences, Inc.’s 29 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this prospective, blinded assessor, randomized trial is to assess opioid use and patient-reported outcomes of EXPAREL as a foundation in postsurgical pain therapy in Transversus Abdominis Plane (TAP) infiltration in lower abdominal surgical procedures.
The purpose of this prospective, blinded assessor, randomized trial is to assess opioid use and patient-reported outcomes of EXPAREL as a foundation in postsurgical pain therapy in Transversus Abdominis Plane (TAP) infiltration in lower abdominal surgical procedures; primary endpoint signal seen during pre-specified interim analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP
Drug: EXPAREL
The placebo control will be established using a grade-2 sham, no infiltration will occur
Drug: Placebo
TAP with EXPAREL
Also known as: bupivacaine liposome injectable suspension.
Placebo
Also known as: Placebo using grade-2 sham, no infiltration
Total Opioid Consumption Post Surgery (Cumulative Total) Until Discharge Readiness or Post Surgery Day 4
Total Opioid Consumption Post Surgery (cumulative total) Until Discharge Readiness or Post Surgery Day 4
Time frame: From surgery through 4 days postsurgery
Overall Benefit of Analgesic Score (OBAS) at Day 3
Severity of postsurgical pain, satisfaction with pain management, and impact of opioid-related symptom distress measured using the Overall Benefit of Analgesic Score (OBAS) - primary endpoint is mean difference in OBAS at Day 3. (0=minimal pain and 4=maximum imaginable pain)
Time frame: Postsurgical day 1 through day 3
Extent and Degree of Anesthetic Blockade
Extent and degree of anesthetic blockage measured using a 5-point sensation scale.
Time frame: Prior to TAP, immediately postoperatively, and daily through discharge or Day 4
Severity of Postsurgical Pain
Severity of postsurgical pain measured using an 11-point numerical rating scale (NRS 0-10).
Time frame: Immediately in PACU postsurgery and prior to pain medication until discharge (or Day 4)
Quality of Recovery
Measured using the Quality of Recovery 15 questionnaire (QoR-15)
Time frame: Daily through Post Op Day 4
Frequency of Patient Calls Post-discharge
Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits
Time frame: Post-discharge through 4 days postsurgery
| Milestone | EXPAREL | Placebo |
|---|---|---|
| Started | 33 | 34 |
| Completed | 30 | 34 |
| Not completed | 3 | 0 |
| Withdrew: Intra-op findings, etc. | 3 | 0 |
Total Opioid Consumption Post Surgery (cumulative total) Until Discharge Readiness or Post Surgery Day 4
| Opioid consumption (mg) | EXPAREL | Placebo |
|---|---|---|
| Total Opioid Consumption Post Surgery (Cumulative Total) Until Discharge Readiness or Post Surgery Day 4 | 3.79 ± NA | 3.72 ± NA |
Severity of postsurgical pain, satisfaction with pain management, and impact of opioid-related symptom distress measured using the Overall Benefit of Analgesic Score (OBAS) - primary endpoint is mean difference in OBAS at Day 3. (0=minimal pain and 4=maximum imaginable pain)
| units on a scale | EXPAREL | Placebo |
|---|---|---|
| Overall Benefit of Analgesic Score (OBAS) at Day 3 | 3.05 ± 0.56 | 4.63 ± 0.56 |
Extent and degree of anesthetic blockage measured using a 5-point sensation scale.
No measurements were reported for this outcome.
Severity of postsurgical pain measured using an 11-point numerical rating scale (NRS 0-10).
No measurements were reported for this outcome.
Measured using the Quality of Recovery 15 questionnaire (QoR-15)
No measurements were reported for this outcome.
Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits
No measurements were reported for this outcome.
Collected over 10 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EXPAREL | — | 1/33 (3%) | 0/33 (0%) |
| Placebo | — | 1/34 (2.9%) | 0/34 (0%) |
| Event | EXPAREL | Placebo |
|---|---|---|
| Postoperative abdominal hemorrhageGastrointestinal disorders | 1/33 | 0/34 |
| Postoperative anemia exacerbationBlood and lymphatic system disorders | 0/33 | 1/34 |
| Subtherapeutic international normalized ration (INR)Investigations | 0/33 | 1/34 |
Who met eligibility criteria
| Age, Customized(participants) | EXPAREL | Placebo | Total |
|---|---|---|---|
| Under 75 | 32 | 33 | 65 |
| Over 75 | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | EXPAREL | Placebo | Total |
|---|---|---|---|
| Female | 27 | 28 | 55 |
| Male | 6 | 6 | 12 |
| Region of Enrollment(participants) | EXPAREL | Placebo | Total |
|---|---|---|---|
| United States | 33 | 34 | 67 |
The record gives a start of Aug 2013, a primary completion of Dec 2013 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2021, 7 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine